R&D Views & Analysis | pharmaphorum

Views & Analysis

Clive Dix: Rebuilding UK biotech

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce.

Views & Analysis

Can in vivo imaging deliver the full potential of immunotherapy

The next generation of immunotherapy? Innate Pharma targets ...

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer.

Views & Analysis

COVID heralds a faster future for drug development (if stake...

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, s

Views & Analysis

Jan van de Winkel: Building Europe’s biotech powerhouse at G...

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010.

Views & Analysis

Is disability the last bastion of the representation debate?

From #MeToo to Black Lives Matter, as a society we have been discussing the relationship between representation and equality more than ever over the last few years.

Digital